

Table 1.20

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2012-2014

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 18.76 (18.72, 18.80) | 18.90 (18.86, 18.94) | 19.00 (18.88, 19.12) |
| Oral Cavity and Pharynx | 0.18 (0.17, 0.18) | 0.18 (0.18, 0.19) | 0.15 (0.14, 0.16) |
| Esophagus | 0.20 (0.20, 0.21) | 0.20 (0.20, 0.21) | 0.22 (0.20, 0.23) |
| Stomach | 0.31 (0.30, 0.32) | 0.27 (0.26, 0.27) | 0.50 (0.48, 0.53) |
| Colon and Rectum | 1.74 (1.72, 1.75) | 1.71 (1.69, 1.72) | 1.98 (1.93, 2.02) |
| Liver and Intrahepatic Bile Duct | 0.52 (0.51, 0.52) | 0.49 (0.48, 0.49) | 0.55 (0.53, 0.57) |
| Pancreas | 1.35 (1.33, 1.36) | 1.32 (1.31, 1.34) | 1.54 (1.50, 1.58) |
| Larynx | 0.05 (0.04, 0.05) | 0.05 (0.04, 0.05) | 0.06 (0.05, 0.07) |
| Lung and Bronchus | 4.73 (4.71, 4.75) | 4.90 (4.88, 4.92) | 4.03 (3.97, 4.09) |
| Melanoma of the Skin | 0.21 (0.20, 0.21) | 0.24 (0.23, 0.24) | 0.04 (0.04, 0.05) |
| Breast | 2.62 (2.61, 2.64) | 2.59 (2.58, 2.61) | 3.16 (3.11, 3.22) |
| Cervix Uteri | 0.22 (0.22, 0.23) | 0.21 (0.20, 0.21) | 0.37 (0.35, 0.39) |
| Corpus and Uterus, NOS | 0.60 (0.59, 0.61) | 0.56 (0.55, 0.57) | 0.98 (0.96, 1.01) |
| Ovary | 0.93 (0.92, 0.93) | 0.96 (0.95, 0.97) | 0.74 (0.72, 0.77) |
| Urinary Bladder | 0.34 (0.34, 0.35) | 0.34 (0.34, 0.35) | 0.35 (0.33, 0.37) |
| Kidney and Renal Pelvis | 0.33 (0.33, 0.34) | 0.34 (0.34, 0.35) | 0.29 (0.27, 0.31) |
| Brain and Other Nervous System | 0.41 (0.41, 0.42) | 0.45 (0.44, 0.46) | 0.23 (0.22, 0.24) |
| Thyroid | 0.07 (0.07, 0.07) | 0.07 (0.06, 0.07) | 0.08 (0.07, 0.09) |
| Hodgkin Lymphoma | 0.03 (0.03, 0.03) | 0.03 (0.03, 0.03) | 0.02 (0.02, 0.03) |
| Non-Hodgkin Lymphoma | 0.66 (0.65, 0.67) | 0.69 (0.68, 0.70) | 0.41 (0.40, 0.43) |
| Myeloma | 0.39 (0.38, 0.40) | 0.35 (0.35, 0.36) | 0.72 (0.69, 0.75) |
| Leukemia | 0.71 (0.70, 0.72) | 0.74 (0.73, 0.75) | 0.54 (0.52, 0.57) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.15 (0.14, 0.15) | 0.15 (0.15, 0.16) | 0.11 (0.10, 0.12) |
| Acute Myeloid Leukemia | 0.28 (0.28, 0.29) | 0.29 (0.29, 0.30) | 0.21 (0.19, 0.22) |
| Chronic Myeloid Leukemia | 0.03 (0.03, 0.04) | 0.03 (0.03, 0.04) | 0.03 (0.02, 0.03) |

Devcan Version 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.20 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2012-2014

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 16.40 (16.13, 16.68) | 15.89 (15.27, 16.56) | 15.89 (15.71, 16.06) |
| Oral Cavity and Pharynx | 0.22 (0.18, 0.26) | 0.09 (0.05, 0.21) | 0.15 (0.13, 0.18) |
| Esophagus | 0.16 (0.13, 0.20) | 0.19 (0.13, 0.32) | 0.13 (0.12, 0.15) |
| Stomach | 0.86 (0.79, 0.94) | 0.51 (0.39, 0.69) | 0.63 (0.60, 0.67) |
| Colon and Rectum | 1.77 (1.67, 1.88) | 1.78 (1.55, 2.07) | 1.62 (1.56, 1.69) |
| Liver and Intrahepatic Bile Duct | 1.17 (1.10, 1.26) | 0.90 (0.75, 1.09) | 0.96 (0.92, 1.01) |
| Pancreas | 1.48 (1.39, 1.57) | 1.02 (0.85, 1.23) | 1.35 (1.29, 1.40) |
| Larynx | 0.02 (0.01, 0.04) | 0.02 (0.01, 0.12) | 0.02 (0.02, 0.04) |
| Lung and Bronchus | 3.41 (3.29, 3.54) | 3.75 (3.45, 4.10) | 2.29 (2.23, 2.36) |
| Melanoma of the Skin | 0.06 (0.05, 0.09) | 0.07 (0.02, 0.20) | 0.09 (0.08, 0.11) |
| Breast | 1.75 (1.66, 1.85) | 1.63 (1.43, 1.89) | 2.14 (2.08, 2.21) |
| Cervix Uteri | 0.23 (0.20, 0.27) | 0.26 (0.20, 0.38) | 0.30 (0.28, 0.33) |
| Corpus and Uterus, NOS | 0.44 (0.40, 0.49) | 0.42 (0.32, 0.57) | 0.55 (0.52, 0.58) |
| Ovary | 0.66 (0.61, 0.72) | 0.72 (0.59, 0.90) | 0.80 (0.76, 0.84) |
| Urinary Bladder | 0.26 (0.22, 0.31) | 0.18 (0.11, 0.33) | 0.26 (0.23, 0.29) |
| Kidney and Renal Pelvis | 0.21 (0.18, 0.26) | 0.53 (0.41, 0.70) | 0.40 (0.37, 0.43) |
| Brain and Other Nervous System | 0.26 (0.23, 0.30) | 0.21 (0.15, 0.33) | 0.34 (0.32, 0.37) |
| Thyroid | 0.12 (0.10, 0.15) | 0.09 (0.03, 0.22) | 0.11 (0.09, 0.13) |
| Hodgkin Lymphoma | 0.02 (0.01, 0.04) | 0.01 (0.00, 0.11) | 0.04 (0.04, 0.06) |
| Non-Hodgkin Lymphoma | 0.65 (0.59, 0.72) | 0.42 (0.32, 0.58) | 0.68 (0.64, 0.72) |
| Myeloma | 0.25 (0.21, 0.30) | 0.38 (0.29, 0.54) | 0.39 (0.36, 0.42) |
| Leukemia | 0.51 (0.46, 0.57) | 0.45 (0.33, 0.62) | 0.60 (0.57, 0.64) |
| Acute Lymphocytic Leukemia | 0.03 (0.02, 0.05) | 0.05 (0.03, 0.15) | 0.06 (0.05, 0.07) |
| Chronic Lymphocytic Leukemia | 0.03 (0.02, 0.05) | 0.03 (0.01, 0.14) | 0.07 (0.06, 0.09) |
| Acute Myeloid Leukemia | 0.26 (0.23, 0.30) | 0.21 (0.13, 0.35) | 0.23 (0.21, 0.25) |
| Chronic Myeloid Leukemia | 0.02 (0.01, 0.05) | 0.00 (0.00, 0.11) | 0.03 (0.02, 0.04) |

Devcan Version 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.